Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v2-FR Version v2-FR
Language French French
Date Updated 2019-08-12 2019-08-12
Drug Identification Number 02230810 02230810
Brand name NUTRINEAL PD4 NUTRINEAL PD4
Common or Proper name NUTRINEAL PD4 NUTRINEAL PD4
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients PHENYLALANINE HISTIDINE TRYPTOPHAN LEUCINE ARGININE SODIUM LACTATE THREONINE ALANINE MAGNESIUM CHLORIDE CALCIUM CHLORIDE SODIUM CHLORIDE DL-METHIONINE GLYCINE PROLINE TYROSINE LYSINE SERINE VALINE ISOLEUCINE PHENYLALANINE HISTIDINE TRYPTOPHAN LEUCINE ARGININE SODIUM LACTATE THREONINE ALANINE MAGNESIUM CHLORIDE CALCIUM CHLORIDE SODIUM CHLORIDE DL-METHIONINE GLYCINE PROLINE TYROSINE LYSINE SERINE VALINE ISOLEUCINE
Strength(s) 57MG 71.4MG 27MG 102MG 107.1MG 448MG 64.6MG 95.1MG 5.1MG 18.4MG 538MG 85MG 51MG 59.5MG 30MG 95.5MG 51MG 139.3MG 85MG 57MG 71.4MG 27MG 102MG 107.1MG 448MG 64.6MG 95.1MG 5.1MG 18.4MG 538MG 85MG 51MG 59.5MG 30MG 95.5MG 51MG 139.3MG 85MG
Dosage form(s) LIQUID LIQUID
Route of administration DIALYSIS DIALYSIS
Packaging size 2.5 L Twinbag 2.5 L Twinbag
ATC code B05ZA B05ZA
ATC description HEMODIALYTICS AND HEMOFILTRATES HEMODIALYTICS AND HEMOFILTRATES
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2020-04-30 2020-04-30
Actual discontinuation date
Remaining supply date 2020-04-30 2020-04-30
Discontinuation status To be discontinued To be discontinued
Discontinuation decision reversal no no
Information on remaining supply
Company comments Nutrineal is indicated for the treatment of protein malnutrition in peritoneal dialysis patients. Peritoneal dialysis patients requiring nutritional supplementation can obtain this through alternate routes such as oral/enteral or parenteral supplementation depending on their specific needs and clinical condition. Peritoneal dialysis can be maintained in patients through the various dialysis solutions available within the Baxter portfolio (Dianeal product line, Physioneal product line or Extraneal). It will be up to the healthcare professional to select the appropriate solution based on the patient needs. Baxter’s timeline to discontinue Nutrineal is approximately one year from official discontinuation notification allowing the healthcare team ample time to determine alternate means of nutritional support based on the patient requirements. Nutrineal is indicated for the treatment of protein malnutrition in peritoneal dialysis patients. Peritoneal dialysis patients requiring nutritional supplementation can obtain this through alternate routes such as oral/enteral or parenteral supplementation depending on their specific needs and clinical condition. Peritoneal dialysis can be maintained in patients through the various dialysis solutions available within the Baxter portfolio (Dianeal product line, Physioneal product line or Extraneal). It will be up to the healthcare professional to select the appropriate solution based on the patient needs. Baxter’s timeline to discontinue Nutrineal is approximately one year from official discontinuation notification allowing the healthcare team ample time to determine alternate means of nutritional support based on the patient requirements.
Health Canada comments